Seema Sheoran's questions to BioCryst Pharmaceuticals Inc (BCRX) leadership • Q4 2024
Question
Seema Sheoran, on for Liisa Bayko, asked about the target product profile for avoralstat in diabetic macular edema (DME) and what investors should look for in the upcoming Phase 1 data.
Answer
Chief Commercial Officer Charlie Gayer outlined the target profile as an infrequent injection, potentially every 3-6 months, for the nearly 50% of DME patients who do not fully respond to anti-VEGF therapies. Chief R&D Officer Dr. Helen Thackray added that the Phase 1 trial will enroll patients directly to assess safety, tolerability, and initial signs of activity, such as changes in edema and visual acuity, after a single injection.